Status:
COMPLETED
Quality of Life Analysis of Arimidex Treatment in Postmenopausal Patients With Breast Cancer
Lead Sponsor:
AstraZeneca
Conditions:
Breast Cancer
Eligibility:
FEMALE
Brief Summary
This is an open label, non-interventional quality of life analysis for Arimidex treated postmenopausal patients in early breast cancer by investigator's questionnaire
Eligibility Criteria
Inclusion
- Provision of informed consent
- Postmenopausal, hormon receptor positive patients with early breast cancer treated with Arimidex
- Investigators are requested to recruit patients only with at least 1 month prior Arimidex treatment.
Exclusion
- Allergy to substance of medication
- Pre-perimenopausal woman
- Woman not eligible for treatment
Key Trial Info
Start Date :
June 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2010
Estimated Enrollment :
1510 Patients enrolled
Trial Details
Trial ID
NCT00692289
Start Date
June 1 2008
End Date
July 1 2010
Last Update
June 6 2012
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Budapest, Hungary
2
Research Site
Komló, Hungary
3
Research Site
Miskolc, Hungary
4
Research Site
Mohács, Hungary